Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Helix, Fulgent Genetics, IDbyDNA, Quantum-Si, More

Helix: James Lu, Marc Stapley

James Lu has been appointed as CEO of Helix, effective June 1. He will replace Marc Stapley, who will become executive chairman of Helix's board of directors. Lu, who is a cofounder of Helix and the firm's president, will also join the board of directors. Stapley previously held various roles at Illumina, including CFO. He joined Helix as CEO in 2019.


Fulgent Genetics: Lawrence Weiss

Fulgent Genetics has appointed Lawrence Weiss to the position of chief medical officer. Weiss will be responsible for expanding Fulgent’s reach in molecular diagnostics and advancing the company's portfolio of oncology testing solutions. He most recently served as CMO of NeoGenomics, prior to which he was lab director for Clarient Diagnostic Services.


IDbyDNA: Neil Gunn, Guochun Liao

Neil Gunn has been appointed as CEO of pathogen detection firm IDbyDNA, succeeding Guochun Liao, the firm's cofounder, in this role. Gunn joins the company from Roche Diagnostics, where he was president and head of the sequencing business unit. Previously, he led commercial operations, global marketing, and the Americas business at Chiron, where he helped introduce HIV and HCV molecular blood screening tests.

Liao will become IDbyDNA's chief innovation officer and serve as the company's president and board chairman.


Quantum-Si: Marijn Dekkers, Ruth Fattori

Single-molecular protein sequencing firm Quantum-Si has appointed Marijn Dekkers and Ruth Fattori to its board of directors. Both individuals have agreed to continue to serve on the board of the combined company subsequent to the closing of the previously announced business combination between Quantum-Si and HighCape Capital Acquisition.

Dekkers is founder and chairman of Novalis LifeSciences. From 2010 to 2016 he was CEO of Bayer AG, and from 2002 to 2009 he was CEO of Thermo Fisher Scientific. Dekkers currently serves on the board of directors for the Foundation for the National Institutes of Health, Georgetown University, Quanterix, and Cerevel Therapeutics.

Fattori is managing partner of Pecksland Partners. She also serves as a senior advisor at the Boston Consulting Group. Most recently, she was executive vice president and chief human resources officer of PepsiCo. She also previously served as executive VP and chief administrative officer for MetLife and chair of the MetLife Foundation.


For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.